The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Th17 May Contribute to Bone Destruction by Modifying Osteoclasts

Th17 May Contribute to Bone Destruction by Modifying Osteoclasts

June 3, 2013 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Up until now, bone physiology has primarily been studied via bone-tissue sectioning and conventional histomorphometric analyses. A new approach by Junichi Kikuta of Osaka University in Japan and colleagues provides additional information on osteoclast behavior and activity in situ. While previous studies have identified RANKL as a critical factor in the terminal differentiation of osteoclasts, the findings, published in the the Journal of Clinical Investigation, describe the role of RANKL-expressing Th17 cells in inflammatory bone destruction.1

You Might Also Like
  • Research Offers Hope of New Therapies to Prevent Bone Loss and Destruction
  • Clues Emerge to Bone Health, Destruction in Rheumatoid Arthritis
  • SSRIs Act Centrally to Cause Bone Loss
Also By This Author
  • Periodontitis May Provide Insight into RA

The authors produced a fluorescent GFP fusion protein from the mouse Tcirg1 locus (a3-GFP mice), thereby labeling mature osteoclasts. They used the fluorescent labeling to calculate a cell deformation index that identified two states for mature osteoclasts: resorbing state (R) and nonresorbing (N) state. They also identified cells that were transitioning between the two states. To further their investigation, the authors developed a chemical fluorescent probe that was capable of detecting bone resorption at specific sites on the bone surface.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In their study, the authors describe how pretreatment of mice with fluorescently labeled RANKL reduced bone-tissue density and stimulated osteoclastogenesis. Moreover, they found that when labeled RANKL was injected intravenously into mice, moving osteoclasts swiftly became static cells, suggesting to the authors an N-to-R transition. This observation was confirmed when the authors applied RANKL to osteoclasts in vitro, and were able to convert N osteoclasts to R osteoclasts. RANKL-expressing Th17 cells had the same effect as RANKL on mature osteoclast function.

“Osteoclasts have been considered to destroy bones continuously once they are formed from monocytoid precursors, and thus to be short lived. By using our intravital bone-imaging technique, we first demonstrated that osteoclasts repeatedly undergo transition between resorbing ‘R’ states, which firmly stick to bones, and nonresorbing ‘N’ states, sliding on the bone surfaces. An inflammatory helper T-cell type, Th17, was shown to contribute to bone destruction by converting N-state osteoclasts into R-type by direct cell-to-cell contact, which is a novel point of action of T cells,” explained Masaru Ishii, MD, PhD, by e-mail. Dr. Ishii is an author on the paper and head of the laboratory where the research was performed.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He elaborated that he was surprised by the dynamic behavior of bone osteoclasts. He was also surprised that Th17 cells seemed to regulate the dynamic movement of osteoclasts by direct cell-to-cell contact. The team hypothesizes that Th17 cells meet mature osteoclasts on erosive surfaces of the inflammatory synovium.


Dr. Pullen is a medical writer based in the Chicago area.

Reference

  1. Kikuta J, Wada Y, Kowada T, et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. J Clin Invest. 2013;123:866-873.

Pages: 1 2 | Single Page

Filed Under: Conditions, Osteoarthritis, Research Reviews Tagged With: Bone Destruction, Osteoclasts, Th17

You Might Also Like:
  • Research Offers Hope of New Therapies to Prevent Bone Loss and Destruction
  • Clues Emerge to Bone Health, Destruction in Rheumatoid Arthritis
  • SSRIs Act Centrally to Cause Bone Loss
  • Salt as a Promoter of Th17 Cells and Autoimmune Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)